Switching between P2Y
Adenosine Monophosphate
/ administration & dosage
Administration, Intravenous
Administration, Oral
Blood Platelets
/ drug effects
Cardiovascular Diseases
/ blood
Clinical Decision-Making
Clopidogrel
/ administration & dosage
Drug Substitution
/ adverse effects
Humans
Platelet Aggregation
/ drug effects
Platelet Aggregation Inhibitors
/ administration & dosage
Prasugrel Hydrochloride
/ administration & dosage
Purinergic P2Y Receptor Antagonists
/ administration & dosage
Receptors, Purinergic P2Y12
/ blood
Ticagrelor
/ administration & dosage
Treatment Outcome
Journal
Vascular pharmacology
ISSN: 1879-3649
Titre abrégé: Vascul Pharmacol
Pays: United States
ID NLM: 101130615
Informations de publication
Date de publication:
05 2019
05 2019
Historique:
received:
21
01
2019
revised:
19
02
2019
accepted:
03
03
2019
pubmed:
17
3
2019
medline:
4
9
2019
entrez:
17
3
2019
Statut:
ppublish
Résumé
The pharmacological and clinical differences of the three recommended oral P2Y
Identifiants
pubmed: 30876967
pii: S1537-1891(19)30011-4
doi: 10.1016/j.vph.2019.03.001
pii:
doi:
Substances chimiques
P2RY12 protein, human
0
Platelet Aggregation Inhibitors
0
Purinergic P2Y Receptor Antagonists
0
Receptors, Purinergic P2Y12
0
Adenosine Monophosphate
415SHH325A
cangrelor
6AQ1Y404U7
Clopidogrel
A74586SNO7
Prasugrel Hydrochloride
G89JQ59I13
Ticagrelor
GLH0314RVC
Types de publication
Journal Article
Review
Langues
eng
Sous-ensembles de citation
IM
Pagination
4-7Informations de copyright
Copyright © 2019 Elsevier Inc. All rights reserved.